Alice Reicin appointed head of development at Merck KGaA's biopharma business

Alise Reicin has been appointed head of global clinical development in the biopharma business of Germany’s Merck KGaA (MRK: DE).

She brings extensive research and development experience, especially in oncology and immunology, and has strong pharma leadership experience, having served as vice president in various capacities in Merck’s R&D for 10 years. Dr Reicin will oversee the clinical development organization and lead the biopharma business. Before joining the company, Reicin was a faculty member at Columbia Medical School, and a physician and researcher at Columbia Presbyterian Hospital.

Luciano Rossetti, head of global research and development, said: "We are honored to have Alise join us. Her impressive experience across diverse areas of clinical research and operations will bring significant value to our organization. She is an accomplished executive whose leadership will serve to significantly advance our clinical development efforts and our strong commitment to enhance our R&D operating model."